Earnings Summary

Achilles Therapeutics Pl-adr’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2023. On a quarterly growth basis, Achilles Therapeutics Pl-adr has generated NaN% jump in its revenue since last 3-months.

Achilles Therapeutics Pl-adr’s net profit jumped 2.56% since last year same period to $-16.85Mn in the Q2 2023. On a quarterly growth basis, Achilles Therapeutics Pl-adr has generated 3.77% jump in its net profits since last 3-months.

Achilles Therapeutics Pl-adr’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2023. On a quarterly growth basis, Achilles Therapeutics Pl-adr has generated NaN% jump in its net profit margins since last 3-months.

Achilles Therapeutics Pl-adr’s earning per share (EPS) estimates for the current quarter stand at -0.45 - a 18.18% jump from last quarter’s estimates.

Achilles Therapeutics Pl-adr’s earning per share (EPS) estimates for the current year stand at -0.45.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Achilles Therapeutics Pl-adr’s return on assets (ROA) stands at -0.19.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Achilles Therapeutics Pl-adr’s return on equity (ROE) stands at -0.35.